Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Fineline Cube Jan 20, 2026
Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Fineline Cube Jan 20, 2026
Company Deals

Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease

Fineline Cube Jan 19, 2026
Company Deals

InventisBio Files for Hong Kong IPO, Betting on Oncology and Metabolic Pipeline

Fineline Cube Jan 16, 2026
Company Deals

Boston Scientific to Acquire Penumbra in $14.5 Billion Deal, Bolsters Thrombectomy Leadership

Fineline Cube Jan 16, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

Fineline Cube Jan 20, 2026
Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Fineline Cube Jan 19, 2026
Company Deals

OrbiMed Raises Over USD 4.3 Billion for Private Investment Funds Focused on Healthcare

Fineline Cube Oct 25, 2023

US-based investment fund giant OrbiMed has announced the successful raising of over USD 4.3 billion...

Company Deals

BMS Regains Full Rights to Mavacamten in China and Asia from LianBio

Fineline Cube Oct 25, 2023

Bristol-Myers Squibb (BMS; NYSE: BMY) is set to regain full control of mavacamten, a treatment...

Company Drug

Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment

Fineline Cube Oct 25, 2023

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...

Company Drug

Jiangsu Aidea’s HIV-1 Drug ACC017 Accepted for NMPA Review in China

Fineline Cube Oct 25, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has announced that the National Medical Products...

Company Drug

Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO

Fineline Cube Oct 24, 2023

Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...

Company Drug

Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO

Fineline Cube Oct 24, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...

Company Drug

Walvax Biotechnology Secures BPOM Approval for Weuphoria Pneumococcal Vaccine

Fineline Cube Oct 24, 2023

China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has announced that it has received market approval...

Policy / Regulatory

NMPA Implements New Measures for Drug Manufacturing Outsourcing by MAHs

Fineline Cube Oct 24, 2023

The National Medical Products Administration (NMPA) has issued a notice detailing new supervision and management...

Company Drug

Ascentage Pharma’s Pelcitoclax Shows Promise in ESMO Study for NSCLC

Fineline Cube Oct 24, 2023

Suzhou-based pharmaceutical company Ascentage Pharma (HKG: 6855) has published the latest results from a Phase...

Company Drug

Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion

Fineline Cube Oct 24, 2023

China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805...

Company Drug

Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial

Fineline Cube Oct 24, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...

Company Drug

Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607

Fineline Cube Oct 24, 2023

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...

Company Medical Device

Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter

Fineline Cube Oct 24, 2023

China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the...

Company Drug

Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO

Fineline Cube Oct 24, 2023

China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...

Company Drug

Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment

Fineline Cube Oct 24, 2023

China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...

Company Deals

Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio

Fineline Cube Oct 24, 2023

Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings,...

Company Deals

J&J MedTech Partners with CED Medical for Neurointerventional Solutions

Fineline Cube Oct 24, 2023

Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd,...

Company Drug

Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023

Fineline Cube Oct 24, 2023

China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...

Company Drug

Janssen’s TAR-200 Shows High Complete Response Rate in Bladder Cancer Study

Fineline Cube Oct 23, 2023

Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has published data from a Phase IIb...

Company Drug

Novartis’ Kisqali Plus Endocrine Therapy Shows Improved Survival in Early Breast Cancer Study

Fineline Cube Oct 23, 2023

Switzerland-based pharmaceutical company Novartis (NYSE: NVS) has announced additional results from an ongoing Phase III...

Posts pagination

1 … 400 401 402 … 611

Recent updates

  • AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal
  • Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease
  • Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data
  • Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise
  • Harbour BioMed Boosts Spruce Stake to 3.8%, Advancing SPR202 for Adrenal Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

AstraZeneca Secures Full Global Rights to AbelZeta’s C‑CAR031 in $630M CAR‑T Deal

Company Drug

Novartis’s Ianalumab Wins FDA Breakthrough Therapy Designation for Sjögren’s Disease

Company Deals

Medtronic and Precision Neuroscience Form First Brain‑Device Alliance to Access Neural Data

Company Drug

Akeso’s Gumokimab NMPA Filing for Ankylosing Spondylitis Expands IL‑17A Franchise

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.